Combination Therapies in Melanoma
Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses promising combination therapies for the treatment of melanoma.
Clinical Pearls
- In the metastatic setting, BRAF, MEK, and checkpoint inhibition is forthcoming
- There are currently trials looking at anti-PD-1 with anti-CTLA-4 therapy
- Dr. Hamid is hopeful that in the future, other targeted immunotherapies and FDA-approved targeted treatment combinations will show survival benefit and be approved and available for use.
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
